Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | LGMN | Q99538 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769730 | 0.81 | MMP2 (0.40) | MMP2MMP9MMP13MMP8CYP11B1 | |
| SCHEMBL770167 | 0.81 | ALDH1A1 (0.46) | — | |
| SCHEMBL13044959 | 0.77 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL3958165 | 0.74 | CYP11B1 (0.44) | MMP2MMP9MMP13MMP8CYP11B1 | |
| SCHEMBL24974211 | 0.73 | CYP11B1 (0.37) | MMP2MMP9MMP13MMP8CYP11B1 | |
| SCHEMBL7280596 | 0.72 | HSD17B10 (0.57) | — | |
| SCHEMBL5291267 | 0.72 | HSD17B10 (0.57) | — | |
| SCHEMBL18246435 | 0.71 | APLNR (0.46) | — | |
| SCHEMBL14636153 | 0.71 | MMP2 (0.38) | MMP2MMP9MMP13MMP8NFE2L2 | |
| SCHEMBL18246739 | 0.71 | APLNR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926274-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| EP-2650282-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9000156-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2141149-B1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2650282-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650283-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2141149-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | MMP2 663/4885MMP9 1417/4885MMP13 3339/4885 |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | MMP2 663/4885MMP9 1417/4885MMP13 3339/4885 |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | MMP2 663/4885MMP9 1417/4885MMP13 3339/4885 |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | MMP2 787/4885MMP9 1666/4885MMP13 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.